Last reviewed · How we verify
bupropion & Citalopram
This combination blocks the reuptake of norepinephrine and dopamine (bupropion) and serotonin (citalopram) to increase their availability in the brain.
This combination blocks the reuptake of norepinephrine and dopamine (bupropion) and serotonin (citalopram) to increase their availability in the brain. Used for Major depressive disorder, Treatment-resistant depression.
At a glance
| Generic name | bupropion & Citalopram |
|---|---|
| Sponsor | University of Colorado, Denver |
| Drug class | Antidepressant combination (NDRI + SSRI) |
| Target | Norepinephrine transporter, dopamine transporter, serotonin transporter |
| Modality | Small molecule |
| Therapeutic area | Psychiatry / Mental Health |
| Phase | FDA-approved |
Mechanism of action
Bupropion is a norepinephrine-dopamine reuptake inhibitor (NDRI) that increases levels of norepinephrine and dopamine in the central nervous system. Citalopram is a selective serotonin reuptake inhibitor (SSRI) that increases serotonin availability. Together, this combination targets multiple monoamine neurotransmitter systems to treat depression and potentially improve mood and motivation.
Approved indications
- Major depressive disorder
- Treatment-resistant depression
Common side effects
- Insomnia
- Nausea
- Headache
- Dry mouth
- Tremor
- Seizure risk (bupropion)
- QT prolongation (citalopram)
Key clinical trials
- Pharmacokinetics and Safety of Commonly Used Drugs in Lactating Women and Breastfed Infants
- Intensified Pharmacological Treatment for Schizophrenia, Major Depressive Disorder and Bipolar Depression After a First-time Treatment Failure (PHASE3)
- Treating Negative Affect in Low Back Pain Patients (PHASE2, PHASE3)
- Neurobiological and Genomic Predictors of Relapse in Depression
- The Effect of a Six Week Intensified Pharmacological Treatment for Bipolar Depression Compared to Treatment as Usual in Subjects Who Had a First-time Treatment Failure on Their First-line Treatment. (PHASE3)
- Clemastine for Improving White Matter and Boosting Antidepressant Response in Late-life Depression (PHASE2)
- Mood Stabilizer (MS)+ Antidepressant vs MS + Placebo in Maintenance of Bipolar Disorder. (PHASE3)
- A Study of Esketamine Nasal Spray Plus a New Standard-of-care Oral Antidepressant or Placebo Nasal Spray Plus a New Standard-of-care Oral Antidepressant in Adult and Elderly Participants With Treatment-resistant Depression (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- bupropion & Citalopram CI brief — competitive landscape report
- bupropion & Citalopram updates RSS · CI watch RSS
- University of Colorado, Denver portfolio CI